Aardvark Therapeutics, Inc.
AARD
$11.81
-$0.14-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 181.64% | 99.43% | 35.89% | 29.92% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 382.27% | 323.20% | 196.16% | 25.38% | |
| Operating Income | -382.27% | -323.20% | -196.16% | -25.38% | |
| Income Before Tax | -327.46% | -330.13% | -98.29% | -42.45% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -327.46% | -330.13% | -98.29% | -42.45% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -327.46% | -330.13% | -98.29% | -42.45% | |
| EBIT | -382.27% | -323.20% | -196.16% | -25.38% | |
| EBITDA | -382.48% | -- | -- | -- | |
| EPS Basic | -28.52% | -319.80% | -97.09% | -42.12% | |
| Normalized Basic EPS | -35.14% | -302.94% | -156.73% | -79.90% | |
| EPS Diluted | -28.52% | -319.80% | -97.09% | -42.12% | |
| Normalized Diluted EPS | -35.14% | -302.94% | -156.73% | -79.90% | |
| Average Basic Shares Outstanding | 232.59% | 2.46% | 0.61% | 0.24% | |
| Average Diluted Shares Outstanding | 232.59% | 2.46% | 0.61% | 0.24% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |